LEXARIA BIOSCIENCE CORP. Net Income (Loss) Attributable to Parent, Diluted
LEXARIA BIOSCIENCE CORP. (LEXX) reported Net Income (Loss) Attributable to Parent, Diluted of $5.00 million for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. net income (loss) attributable to parent, diluted for the quarter ending 2026-05-31 was $2.00M, a 47.37% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. net income (loss) attributable to parent, diluted for the quarter ending 2026-02-28 was $1.40M, a 48.15% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. net income (loss) attributable to parent, diluted for the quarter ending 2025-11-30 was $1.60M, a 40.74% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. net income (loss) attributable to parent, diluted for the quarter ending 2025-08-31 was $2.70M, a 22.73% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. net income (loss) attributable to parent, diluted for fiscal 2025 was $11.90M, a 105.17% increase from fiscal 2024.
- LEXARIA BIOSCIENCE CORP. net income (loss) attributable to parent, diluted for fiscal 2024 was $5.80M, a 13.43% decline from fiscal 2023.
- LEXARIA BIOSCIENCE CORP. net income (loss) attributable to parent, diluted for fiscal 2023 was $6.70M, a 8.72% decline from fiscal 2022.
- LEXARIA BIOSCIENCE CORP. net income (loss) attributable to parent, diluted for fiscal 2022 was $7.34M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month | Net Income (Loss) Attributable to Parent, Diluted 12 month |
|---|---|---|---|---|
| 2026-05-31 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-07-13 | $3.40M derived: sum of 2 quarters · filed 2026-07-13 | $5.00M 10-Q · filed 2026-07-13 | $7.70M derived: sum of 4 quarters · filed 2026-07-13 |
| 2026-02-28 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-04-13 | $3.00M 10-Q · filed 2026-04-13 | $5.70M derived: sum of 3 quarters · filed 2026-04-13 | $9.50M derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-11-30 | $1.60M 10-Q · filed 2026-01-13 | $4.30M derived: sum of 2 quarters · filed 2026-01-13 | $8.10M derived: sum of 3 quarters · filed 2026-07-13 | $10.80M derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-08-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | $6.50M derived: sum of 2 quarters · filed 2026-07-13 | $9.20M derived: sum of 3 quarters · filed 2026-07-13 | $11.90M 10-K · filed 2025-11-28 |
| 2025-05-31 | $3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-07-13 | $6.50M derived: sum of 2 quarters · filed 2026-07-13 | $9.20M 10-Q · filed 2026-07-13 | $11.40M derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-02-28 | $2.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-04-13 | $5.40M 10-Q · filed 2026-04-13 | $7.60M derived: sum of 3 quarters · filed 2026-04-13 | $9.40M derived: sum of 4 quarters · filed 2026-04-13 |
| 2024-11-30 | $2.70M 10-Q · filed 2026-01-13 | $4.90M derived: sum of 2 quarters · filed 2026-01-13 | $6.70M derived: sum of 3 quarters · filed 2026-01-13 | $7.30M derived: sum of 4 quarters · filed 2026-01-13 |
| 2024-08-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | $4.00M derived: sum of 2 quarters · filed 2025-11-28 | $4.60M derived: sum of 3 quarters · filed 2025-11-28 | $5.80M 10-K · filed 2025-11-28 |
| 2024-05-31 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-07-14 | $2.40M derived: sum of 2 quarters · filed 2025-07-14 | $3.60M 10-Q · filed 2025-07-14 | $4.80M derived: sum of 4 quarters · filed 2025-07-14 |
| 2024-02-29 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-04-14 | $1.80M 10-Q · filed 2025-04-14 | $3.00M derived: sum of 3 quarters · filed 2025-04-14 | $5.40M derived: sum of 4 quarters · filed 2025-04-14 |
| 2023-11-30 | $1.20M 10-Q · filed 2025-01-10 | $2.40M derived: sum of 2 quarters · filed 2025-01-10 | $4.80M derived: sum of 3 quarters · filed 2025-01-10 | $6.10M derived: sum of 4 quarters · filed 2025-01-10 |
| 2023-08-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $3.60M derived: sum of 2 quarters · filed 2024-11-26 | $4.90M derived: sum of 3 quarters · filed 2024-11-26 | $6.70M 10-K · filed 2024-11-26 |
| 2023-05-31 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-07-12 | $3.70M derived: sum of 2 quarters · filed 2024-07-12 | $5.50M 10-Q · filed 2024-07-12 | |
| 2023-02-28 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-04-09 | $3.10M 10-Q · filed 2024-04-09 | ||
| 2022-11-30 | $1.80M 10-Q · filed 2024-01-12 | |||
| 2022-08-31 | $7.34M 10-K · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |